KLRS

Company Overview — What Does Allovir, Inc. Do?

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir, Inc. (KLRS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Diana M. Brainard and employs approximately 110 people. With a market capitalization of $136M, KLRS is one of the notable companies in the Healthcare sector.

Allovir, Inc. (KLRS) Stock Rating — Avoid (April 2026)

As of April 2026, Allovir, Inc. receives a Avoid rating with a composite score of 26.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.KLRS ranks #4,168 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Allovir, Inc. ranks #738 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KLRS Stock Price and 52-Week Range

Allovir, Inc. (KLRS) currently trades at $6.30. The stock gained $0.23 (3.8%) in the most recent trading session. The 52-week high for KLRS is $12.90, which means the stock is currently trading -51.2% from its annual peak. The 52-week low is $2.14, putting the stock 194.4% above its annual trough. Recent trading volume was 63K shares, suggesting relatively thin trading activity.

Is KLRS Overvalued or Undervalued? — Valuation Analysis

Allovir, Inc. (KLRS) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.54x, versus the sector average of 2.75x.

At current multiples, Allovir, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Allovir, Inc. Profitability — ROE, Margins, and Quality Score

Allovir, Inc. (KLRS) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -170.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -88.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KLRS Debt, Balance Sheet, and Financial Health

Allovir, Inc. has a debt-to-equity ratio of 94.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 12.89x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $42M.

KLRS has a beta of 0.90, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Allovir, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Allovir, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Allovir, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.64. Net income for the quarter was $-72M. Operating income came in at $-73M.

In Q3 2025, Allovir, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.64. Net income for the quarter was $-12M. Operating income came in at $-13M.

In Q2 2025, Allovir, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.61. Net income for the quarter was $-11M. Operating income came in at $-12M.

In Q1 2025, Allovir, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.52. Net income for the quarter was $-10M. Operating income came in at $-10M.

Over the past 8 quarters, Allovir, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing KLRS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KLRS Dividend Yield and Income Analysis

Allovir, Inc. (KLRS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KLRS Momentum and Technical Analysis Profile

Allovir, Inc. (KLRS) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

KLRS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Allovir, Inc. (KLRS) ranks #738 out of 838 stocks based on the Blank Capital composite score. This places KLRS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KLRS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KLRS vs S&P 500 (SPY) comparison to assess how Allovir, Inc. stacks up against the broader market across all factor dimensions.

KLRS Next Earnings Date

No upcoming earnings date has been announced for Allovir, Inc. (KLRS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KLRS? — Investment Thesis Summary

The quantitative profile for Allovir, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Allovir, Inc. (KLRS) earns a Avoid rating with a composite score of 26.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KLRS stock.

Related Resources for KLRS Investors

Explore more research and tools: KLRS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KLRS head-to-head with peers: KLRS vs AZN, KLRS vs SLGL, KLRS vs VMD.